Piper Jaffray analyst David Amsellem downgraded Allergan (AGN) to Neutral and lowered his price target for the maker of Botox to $238 from $311. The stock closed Friday up 74c to $217.13.
After looking at U.S. prescription volumes, Amsellem sees "enough items of concern" that call into question Allergan's ability to deliver long-term double-digit annual earnings growth. While a valuation premium to Allergan's specialty pharma peers is reasonable, the current premium "is excessive," Amsellem tells investors in a research note.
Comments
Log in or sign up to join the conversation.